Skip to main content

Table 4 Marginal costs between contingent NIPT vs current practice by varying key input parameters: univariate sensitivity analyses results

From: Introducing cell-free DNA noninvasive testing in a Down syndrome public health screening program: a budget impact analysis

Parameter

Value

Total costs current practice (CAD$)

Total costs Contingent NIPT (CAD$)

Costs difference (Contingent NIPT minus Current practice) ($)

Cost NIPT

1000

7,082,285

7,372,622

290,337

100

7,082,285

5,744,853

−1,337,432

Cost amniocentesis

1000

7,322,744

7,015,881

−306,863

600

6,613,477

6,974,502

361,025

Positive screen SIPS

5%

7,360,645

7,007,644

−353,00

2,50%

6,455,110

6,987,523

532,413

Amniocentesis uptake

95%

7,167,436

7,003,767

−163,669

60%

6,571,382

6,993,807

422,425

NIPT uptake

95%

7,082,285

7,086,891

4606

60%

7,082,285

6,491,623

−59,066

Screening participation uptake

90%

8,960,783

8,832,034

−128,749

40%

6,612,494

6,544,141

−68,353